Actively Recruiting
Randomized Study Comparing Two Oral Vapendavir Doses With Placebo for Rhinovirus Infection in COPD Adults
Led by Altesa Biosciences, Inc. · Updated on 2026-10-22
180
Participants Needed
46
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two different oral doses of vapendavir compared to a placebo to find the right dose for reducing the severity and duration of respiratory symptoms caused by rhinovirus infections in people with chronic obstructive pulmonary disease COPD. This phase 2 clinical trial involves adult participants aged 40 to 85 years who have a confirmed COPD diagnosis and recent history of acute exacerbations. Participants will be randomly assigned to one of three groups one receiving 1000 mg of vapendavir, another receiving 500 mg of vapendavir, and the third receiving a placebo. The first dose is taken at the study site with food, followed by doses at home once daily with food for a total of seven doses. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will complete daily evaluations of respiratory symptoms and severity using patient-reported outcome tools, including the Evaluating Respiratory Symptoms E-RS and Patient Global Impression of Severity PGIS scales. Lung function tests and oscillometry measurements will be conducted at multiple time points up to 42 days. The study aims to measure changes in respiratory symptoms and lung function to assess treatment impact and safety. Participation lasts for up to 12 weeks including baseline, treatment, and follow-up periods.
CONDITIONS
Brief Title
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Research Team
K
Karen Fusaro
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here